Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss

Lyme disease is an illness caused by bacteria most commonly spread to humans from ticks. It can cause arthritis, muscle ...

Pfizer Lyme vaccine shows more than 70% efficacy but misses key statistical goal

There hasn't been an approved Lyme disease vaccine for more than 20 years, after GSK pulled its shot due to a lack of demand.

Pfizer’s Lyme Vaccine Shows Strong Efficacy, but Misses Mark in Study

The drugmaker is seeking regulatory review for the first new shot to combat the disease in decades.

Lyme disease vaccine 70 percent effective: Pfizer

A Lyme disease vaccine produced by Pfizer and Valneva was deemed 70 percent effective by the companies after they reviewed ...
Fierce Biotech

Pfizer, Valneva blame low Lyme cases for phase 3 vaccine fail but still plan approval push

Pfizer and Valneva have blamed “fewer than anticipated” Lyme disease cases for the failure of their phase 3 trial to hit its ...

Pfizer and French partner to seek approval for Lyme disease vaccine after late-stage trial

Pharmaceutical giant Pfizer and French partner Valneva on Monday said they planned to seek regulatory approval for a Lyme ...

Pfizer’s Lyme vaccine shows efficacy, but misses key statistical hurdle

The vaccine could represent a weapon for preventing Lyme, a bacterial infection carried by ticks that is diagnosed and ...

Lyme disease vaccine shows over 70% efficacy, but phase three misses main goal

An experimental vaccine for Lyme disease is broadly effective, pharmaceutical companies Pfizer and Valneva announced Monday; ...

Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial

Vaccine candidate PF-07307405 (LB6V) demonstrated more than 70% efficacy in preventing Lyme disease in individuals aged five years and above -- The investigational vaccine candidate was well tolerated ...
STAT

Pfizer’s Lyme vaccine results set up tricky regulatory path

New results on Pfizer's Lyme disease vaccine, how the Middle East conflict could strain drug supply chains, and more biotech ...

Pfizer Lyme vaccine shows 70% efficacy, misses trial goal

Pfizer wants to fill a 20-year void in human Lyme disease vaccines, but must win over regulators under a vaccine-skeptical ...

Lyme disease vaccine shows 70 percent efficacy, Pfizer says

If approved by regulators, it could become the only Lyme disease vaccine available for people — although it would not be the ...